Truist Securities Maintains Buy on Verona Pharma, Raises Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee maintains a Buy rating on Verona Pharma (NASDAQ:VRNA) and raises the price target from $32 to $38.
June 28, 2024 | 4:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities analyst Joon Lee has reaffirmed a Buy rating on Verona Pharma and increased the price target from $32 to $38.
The reaffirmation of a Buy rating and an increased price target from a reputable analyst can positively influence investor sentiment and potentially drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100